Top

Endocrine

Published in:

01-07-2019 | Original Article

Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells

Authors: Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Seong Jin Lee

Published in: Endocrine | Issue 1/2019

Abstract

Purpose

The impact of evodiamine in combination with histone deacetylase (HDAC) inhibitors on survival of thyroid carcinoma cells was identified.

Methods

TPC-1 and SW1736 human thyroid carcinoma cells were used.

Results

After treatment with evodiamine and PXD101, cell viability, the percentage of viable cells and Bcl2 protein levels decreased, whereas cytotoxic activity, the percentage of apoptotic cells, the protein levels of γH2AX, acetyl. histone H3 and cleaved PARP, and reactive oxygen species (ROS) production increased. In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of γH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio. Furthermore, all of the combination index values were <1.0, suggesting synergistic cytotoxicity of two agents. Wortmannin decreased cell viability and the percentage of viable cells, whereas it increased cytotoxic activity and the percentage of apoptotic cells without alteration in ROS production. The changes in cells treated with both evodiamine and suberoylanilide hydroxamic acid or trichostatin A were similar to those in cells treated with both evodiamine and PXD101.

Conclusions

Our results demonstrate that evodiamine synergizes with HDAC inhibitors in inducing cytotoxic activities by involving survival-related proteins and ROS in thyroid carcinoma cells. Moreover, repression of PI3K/Akt signaling synergistically reinforces cytotoxicity of evodiamine combined with HDAC inhibitors in thyroid carcinoma cells.

Available only for authorised users

M. Molina-Vega, J. García-Alemán, A. Sebastián-Ochoa, I. Mancha-Doblas, J.M. Trigo-Pérez, F. Tinahones-Madueño, Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine 59, 395–401 (2018)CrossRefPubMed

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral

R.C. Smallridge, K.B. Ain, S.L. Asa, K.C. Bible, J.D. Brierley, K.D. Burman, E. Kebebew, N.Y. Lee, Y.E. Nikiforov, M.S. Rosenthal, M.H. Shah, A.R. Shaha, R.M. Tuttle, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22, 1104–1139 (2012)CrossRefPubMed

H. Yu, H. Jin, W. Gong, Z. Wang, H. Liang, Pharmacological actions of multi-target-directed evodiamine. Molecules 18, 1826–1843 (2013)CrossRefPubMedPubMedCentral

J. Jiang, C. Hu, Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 14, 1852–1859 (2009)CrossRefPubMedPubMedCentral

Y. Takada, Y. Kobayashi, B.B. Aggarwal, Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 280, 17203–17212 (2005)CrossRefPubMed

C. Wang, S. Li, M.W. Wang, Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol. In Vitro 24, 898–904 (2010)CrossRefPubMed

F. Yang, L. Shi, T. Liang, L. Ji, G. Zhang, Y. Shen, F. Zhu, L. Xu, Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 485, 54–61 (2017)CrossRefPubMed

M.C. Chen, C.H. Yu, S.W. Wang, H.F. Pu, S.F. Kan, L.C. Lin, C.W. Chi, L.L. Ho, C.H. Lee, P.S. Wang, Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J. Cell. Biochem. 110, 1495–1503 (2010)CrossRefPubMed

10.

C.C. Chien, M.S. Wu, S.C. Shen, C.H. Ko, C.H. Chen, L.L. Yang, Y.C. Chen, Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine. PLoS ONE 9, e99729 (2014)CrossRefPubMedPubMedCentral

11.

C. Fang, J. Zhang, D. Qi, X. Fan, J. Luo, L. Liu, Q. Tan, Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells. PLoS ONE 9, e115204 (2014)CrossRefPubMedPubMedCentral

12.

L. Lin, L. Ren, L. Wen, Y. Wang, J. Qi, Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells. Mol. Med. Rep. 14, 2832–2838 (2016)CrossRefPubMed

13.

Z.J. Meng, N. Wu, Y. Liu, K.J. Shu, X. Zou, R.X. Zhang, C.J. Pi, B.C. He, Z.Y. Ke, L. Chen, Z.L. Deng, L.J. Yin, Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling. Oncol. Rep. 34, 1388–1396 (2015)CrossRefPubMed

14.

W.T. Wei, H. Chen, Z.H. Wang, Z.L. Ni, H.B. Liu, H.F. Tong, H.C. Guo, D.L. Liu, S.Z. Lin, Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int. J. Biol. Sci. 8, 1–14 (2012)CrossRefPubMed

15.

S. Wang, L. Wang, Z. Shi, Z. Zhong, M. Chen, Y. Wang, Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein. PLoS ONE 9, e97512 (2014)CrossRefPubMedPubMedCentral

16.

C.H. Liao, S.L. Pan, J.H. Guh, Y.L. Chang, H.C. Pai, C.H. Lin, C.M. Teng, Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 26, 968–975 (2005)CrossRefPubMed

17.

Z.F. Zhong, W. Tan, S.P. Wang, W.A. Qiang, Y.T. Wang, Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells. Sci. Rep. 5, 16415 (2015)CrossRefPubMedPubMedCentral

18.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, S.J. Lee, Evodiamine suppresses survival, proliferation, migration and epithelial-mesenchymal transition of thyroid carcinoma cells. Anticancer Res. 38, 6339–6352 (2018)CrossRefPubMed

19.

P.A. Marks, M. Dokmanovic, Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497–1511 (2005)CrossRefPubMed

20.

C. Robert, F.V. Rassool, HDAC inhibitors: roles of DNA damage and repair. Adv. Cancer Res. 116, 87–129 (2012)CrossRefPubMed

21.

S.F. Lin, J.D. Lin, T.C. Chou, Y.Y. Huang, R.J. Wong, Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS ONE 8, e77684 (2013)CrossRefPubMedPubMedCentral

22.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 100, E253–E261 (2015)CrossRefPubMed

23.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Endocrine 51, 274–282 (2016)CrossRefPubMed

24.

Q.T. Luong, J. O’Kelly, G.D. Braunstein, J.M. Hershman, H.P. Koeffler, Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin. Cancer Res. 12, 5570–5577 (2006)CrossRefPubMed

25.

I. Clinckspoor, L. Verlinden, L. Overbergh, C. Korch, R. Bouillon, C. Mathieu, A. Verstuyf, B. Decallonne, 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. J. Steroid Biochem. Mol. Biol. 124, 1–9 (2011)CrossRefPubMed

26.

R. Zarnegar, L. Brunaud, H. Kanauchi, M. Wong, M. Fung, D. Ginzinger, Q.Y. Duh, O.H. Clark, Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using trichostatin A, a histone deacetylase inhibitor. Surgery 132, 984–990 (2002)CrossRefPubMed

27.

S. He, G. Dong, Z. Wang, W. Chen, Y. Huang, Z. Li, Y. Jiang, N. Liu, J. Yao, Z. Miao, W. Zhang, C. Sheng, Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors. ACS Med. Chem. Lett. 6, 239–243 (2015)CrossRefPubMedPubMedCentral

28.

Y.L. Li, N.Y. Zhang, X. Hu, J.L. Chen, M.J. Rao, L.W. Wu, Q.Y. Li, B. Zhang, W. Yan, C. Zhang, Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia. Biochem. Biophys. Res. Commun. 498, 481–486 (2018)CrossRefPubMed

29.

M. Xing, Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20, 697–706 (2010)CrossRefPubMedPubMedCentral

30.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Hsp70 inhibition potentiates radicicol-induced cell death in anaplastic thyroid carcinoma cells. Anticancer Res. 34, 4829–4837 (2014)PubMed

31.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells. Endocrine 48, 886–893 (2015)CrossRefPubMed

32.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells. Biomed. Pharmacother. 83, 22–32 (2016)CrossRefPubMed

33.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells. Endocrine 59, 383–394 (2018)CrossRefPubMed

34.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells. J. Endocrinol. Invest. 41, 677–689 (2018)CrossRefPubMed

35.

Y.J. Kim, H.-J. Hwang, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, S.J. Lee, Enigma plays roles in survival of thyroid carcinoma cells through PI3K/AKT signaling and survivin. Anticancer Res. 38, 3515–3525 (2018)CrossRefPubMed

36.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAF^V600E. J. Endocrinol. Invest. 36, 1099–1104 (2013)PubMed

37.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells. Horm. Metab. Res. 45, 408–414 (2013)CrossRefPubMed

38.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in anaplastic thyroid carcinoma cells. Anticancer Res. 35, 6529–6537 (2015)PubMed

39.

S. Cory, J.M. Adams, The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647–656 (2002)CrossRefPubMed

40.

S. Cory, J.M. Adams, Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8, 5–6 (2005)CrossRefPubMed

41.

R.E. Schweppe, J.P. Klopper, C. Korch, U. Pugazhenthi, M. Benezra, J.A. Knauf, J.A. Fagin, L.A. Marlow, J.A. Copland, R.C. Smallridge, B.R. Haugen, Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93, 4331–4341 (2008)CrossRefPubMedPubMedCentral

42.

Z. Lv, D. Zhao, R. Liu, J. Guo, Y. Lin, M. Zhang, Evodiamine inhibits proliferation of human papillary thyroid cancer cell line K1 by regulating of PI3K/Akt signaling pathway. Int. J. Clin. Exp. Med. 9, 15216–15225 (2016)

43.

J.R. Testa, P.N. Tsichlis, AKT signaling in normal and malignant cells. Oncogene 24, 7391–7393 (2005)CrossRefPubMed

Title: Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells
Authors: Si Hyoung Kim
Jun Goo Kang
Chul Sik Kim
Sung-Hee Ihm
Moon Gi Choi
Seong Jin Lee
Publication date: 01-07-2019
Publisher: Springer US
Published in: Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-01885-1

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves’ disease

Hyperthyroidism influences renal function

Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials

Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?

Comparison of stress response following microwave ablation and surgical resection of benign thyroid nodules

CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing’s disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page